Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15592299 | 0.88 | CYP1A2 (0.66) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL14290329 | 0.87 | RAB9A (0.67) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL5555262 | 0.86 | GAA (0.74) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL9809561 | 0.85 | RAB9A (0.76) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL17822214 | 0.85 | EPHX2 (0.75) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL678984 | 0.84 | EPHX2 (0.70) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL29560373 | 0.84 | EPHX2 (0.70) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL9763664 | 0.84 | EPHX2 (0.73) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL5483064 | 0.84 | EPHX2 (0.73) | KMT2AMEN1TDP1RAB9AEPHX2 | |
| SCHEMBL21090097 | 0.83 | RAB9A (0.62) | KMT2AMEN1TDP1RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| EP-2528898-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | Kareus Therapeutics SA (FR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | KMT2A 3121/4885MEN1 4437/4885TDP1 2683/4885 |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | KMT2A 3121/4885MEN1 4437/4885TDP1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.